Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis

Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis

Abstract Background To verify whether serum levels of reactive oxygen metabolites (ROM) are predictive of future clinical remission in patients with rheumatoid arthritis (RA) receiving tocilizumab (TCZ) therapy. Methods A total of 46 patients with RA receiving TCZ therapy were enrolled in this study...

Full description

Bibliographic Details
Main Authors: Arata Nakajima, Keiichiro Terayama, Masato Sonobe, Yasuchika Aoki, Hiroshi Takahashi, Yorikazu Akatsu, Junya Saito, Shinji Taniguchi, Manabu Yamada, Ayako Kubota, Koichi Nakagawa
Format: Article
Language:English
Published: BMC 2019-12-01
Series:BMC Rheumatology
Subjects:
Reactive oxygen metabolites
Tocilizumab
Remission
Rheumatoid arthritis
Biomarker
Online Access:https://doi.org/10.1186/s41927-019-0096-1

Similar Items

Similar Items